Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, ul. Debinki 7, 80-211 Gdansk, Poland.
Clin Chim Acta. 2010 Dec 14;411(23-24):2079-82. doi: 10.1016/j.cca.2010.09.009. Epub 2010 Sep 16.
Accelerated atherosclerosis is a characteristic feature of chronic kidney disease (CKD). CD36 is a scavenger receptor which contributes to foam cell formation, an early crucial step in atherosclerosis development. Recently, a soluble form of CD36 (sCD36) has been discovered. The aim of the study was to develop an ELISA method for quantitative sCD36 evaluation and to measure it in a cohort of CKD stage 5 patients.
A novel monoclonal antibody-based sandwich ELISA for sCD36 evaluation was developed and verified by repeated optimization procedures. Serum concentration of sCD36 was then analyzed in a cohort of 228 CKD stage 5 patients prior to dialysis initiation. Additionally, samples from a control group of 73 healthy, age and gender-matched subjects were evaluated.
The novel CD36 ELISA assay had a recovery of at least 90%, and intra- and inter-assay variability of 6 and 11%, respectively. Concentration of serum sCD36 in CKD patients was significantly increased as compared to controls, and associated with the use of HMG-CoA reductase inhibitors (statins) and the presence of diabetes mellitus (DM). Patients above the 75th percentile of sCD36 concentration were at increased risk of 3-year cardiovascular mortality, as compared to the rest of the cohort [HR 2.85 (1.09-7.59) p=0.03].
For the first time, sCD36 was assessed quantitatively in a group of patients and showed associations with DM, CKD, and statin use. Furthermore, the concentration of sCD36 predicted cardiovascular mortality in CKD stage 5 patients.
动脉粥样硬化加速是慢性肾脏病（CKD）的一个特征。CD36 是一种清道夫受体，有助于泡沫细胞的形成，这是动脉粥样硬化发展的早期关键步骤。最近，发现了一种可溶性 CD36（sCD36）形式。本研究旨在开发一种用于定量评估 sCD36 的 ELISA 方法，并在 CKD 5 期患者队列中进行测量。
开发了一种基于新型单克隆抗体的 sCD36 夹心 ELISA，并通过反复优化程序进行了验证。然后，在开始透析之前，分析了 228 名 CKD 5 期患者队列中的 sCD36 血清浓度。此外，还评估了 73 名健康、年龄和性别匹配的对照组样本。
新型 CD36 ELISA 测定法的回收率至少为 90%，且批内和批间变异性分别为 6%和 11%。与对照组相比，CKD 患者的血清 sCD36 浓度明显升高，与使用 HMG-CoA 还原酶抑制剂（他汀类药物）和糖尿病（DM）有关。与队列的其余部分相比，sCD36 浓度处于第 75 百分位数以上的患者发生 3 年心血管死亡率的风险增加[风险比 2.85（1.09-7.59），p=0.03]。
这是首次在一组患者中定量评估 sCD36，并显示与 DM、CKD 和他汀类药物的使用有关。此外，sCD36 浓度预测了 CKD 5 期患者的心血管死亡率。
